HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting

Stock News

2025/10/28

TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.

The company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.

Notably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.

The company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1195241532"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195241532\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195241532?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 11:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195241532","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.</p>\n<p>The company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.</p>\n<p>Notably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.</p>\n<p>The company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | TYK MEDICINES-B (02410) Rises Nearly 7% Before Noon as Company Presents Positive Clinical Data on Multiple CDK Inhibitors at ESMO Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-28 11:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.</p>\n<p>The company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.</p>\n<p>Notably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.</p>\n<p>The company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1195241532","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195241532","pubTimestamp":1761623776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million. The company recently announced that early clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B","09939":"开拓药业-B","BK1515":"抗疫概念"},"translate_title":"港股动向|泰克医药-B(02410)午盘前涨近7%公司在ESMO年会上公布多款CDK抑制剂积极临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"09939":1},"content_text":"TYK MEDICINES-B (02410) surged nearly 7% before noon, gaining 5.82% to HKD 15.08 by the time of writing, with a turnover of HKD 73.088 million.\nThe company recently announced that early clinical research results for three of its key cyclin-dependent kinase inhibitors (CDKi) drugs—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—were presented in poster format at the 2025 ESMO Annual Meeting. The ESMO 2025 conference was held from October 17 to 21 in Berlin, Germany.\nNotably, at the World Conference on Lung Cancer in September 2025, TYK MEDICINES-B's Phase II pivotal trial of Aidotinib (TY-9591) for non-small cell lung cancer with brain metastases drew significant attention from peers. Aidotinib is a highly selective small-molecule inhibitor developed by the company for EGFR classical mutations.\nThe company completed enrollment of 224 patients for conditional approval eligibility in November 2024 and submitted a pre-NDA application in April 2025. A formal conditional New Drug Application (NDA) is expected to be filed in Q4 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}